(Q36764939)

16 August 2017

1 reference

title

PANVAC-VF: poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma (English)

1 reference

16 August 2017

3

James L Gulley

1 reference

16 August 2017

Ravi A Madan

1

1 reference

PubMed ID

17373905

16 August 2017

Philip M Arlen

series ordinal

2

1 reference

PubMed ID

17373905

16 August 2017

language of work or name

English

0 references

publication date

1 April 2007

1 reference

Expert Opinion on Biological Therapy

16 August 2017

1 reference

16 August 2017

7

1 reference

16 August 2017

543-554

1 reference

16 August 2017

4

1 reference

TRICOM: enhanced vaccines as anticancer therapy

16 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.543

Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.543

Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.543

Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.543

Analyses of recombinant vaccinia and fowlpox vaccine vectors expressing transgenes for two human tumor antigens and three human costimulatory molecules.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.543

21 January 2018

Cancer statistics, 2006

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.543

Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcino

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.543

What makes MUC1 a tumor antigen?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.543

Human MUC1 oncoprotein regulates p53-responsive gene transcription in the genotoxic stress response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.543

MUC1 oncoprotein stabilizes and activates estrogen receptor alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.543

Presentation of MUC1 tumor antigen by class I MHC and CTL function correlate with the glycosylation state of the protein taken Up by dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.543

Deregulated expression of the human tumor marker CEA and CEA family member CEACAM6 disrupts tissue architecture and blocks colonocyte differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.543

Carcinoembryonic antigen enhances metastatic potential of human colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.543

Poxvirus vaccines for cancer and HIV therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.543

Boosting T cell costimulation in cancer: the possibilities seem endless

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.543

Peptide binding to MHC class I molecules: implications for antigenic peptide prediction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.543

Altered peptide ligand design: altering immune responses to class I MHC/peptide complexes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.543

A human cytotoxic T-lymphocyte epitope and its agonist epitope from the nonvariable number of tandem repeat sequence of MUC-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.543

Agonist peptide from a cytotoxic t-lymphocyte epitope of human carcinoembryonic antigen stimulates production of tc1-type cytokines and increases tyrosine phosphorylation more efficiently than cognate peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.543

Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.543

Selective induction of high avidity CTL by altering the balance of signals from APC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.543

Multiple costimulatory modalities enhance CTL avidity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.543

Induction of higher-avidity human CTLs by vector-mediated enhanced costimulation of antigen-presenting cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.543

Vaccines with enhanced costimulation maintain high avidity memory CTL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.543

Specific immunotherapy using a recombinant vaccinia virus expressing human carcinoembryonic antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.543

Human B cells that hyperexpress a triad of costimulatory molecules via avipox-vector infection: an alternative source of efficient antigen-presenting cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.543

Enhancing the potency of peptide-pulsed antigen presenting cells by vector-driven hyperexpression of a triad of costimulatory molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.543

Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.543

Overcoming inhibition of antibody responses to a malaria recombinant vaccinia virus caused by prior exposure to wild type virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.543

Avipox virus-vectored Japanese encephalitis virus vaccines: use as vaccine candidates in combination with purified subunit immunogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.543

Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.543

Development of the PANVAC-VF vaccine for pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.543

The effects of γ-interferon combined with 5-fluorouracil or 5-fluoro-2′-deoxyuridine on proliferation and antigen expression in a panel of human colorectal cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.543

Mechanism of synergy of levamisole and fluorouracil: induction of human leukocyte antigen class I in a colorectal cancer cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.543

Treatment of human colon carcinoma cell lines with anti-neoplastic agents enhances their lytic sensitivity to antigen-specific CD8+ cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.543

Cellular immunity in breast cancer patients completing taxane treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.543

A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.543

External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.543

Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.543

Combination chemotherapy and radiation of human squamous cell carcinoma of the head and neck augments CTL-mediated lysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.543

Combination of a poxvirus-based vaccine with a cyclooxygenase-2 inhibitor (celecoxib) elicits antitumor immunity and long-term survival in CEA.Tg/MIN mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.543

A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.543

The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.543

Radiation therapy and tamoxifen: concurrent or sequential? That is the question

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.543

Pancreatic cancer: a review of recent advances

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.543

Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.543

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.543

21 January 2018

Identifiers

DOI

10.1517/14712598.7.4.543

1 reference

16 August 2017

1 reference

PubMed ID

17373905